Related Experiment Video
Updated: Mar 31, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
1Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract:
Ameloblastoma is an odontogenic neoplasm whose molecular pathogenesis has only recently been elucidated. The discovery of recurrent activating mutations in FGFR2, BRAF, and RAS in a large majority of ameloblastomas has implicated dysregulation of MAPK pathway signaling as a critical step in the pathogenesis of this tumor. Some degree of controversy exists regarding the role of mutations affecting the sonic hedgehog (SHH) pathway, specifically Smoothened (SMO), which have been postulated to serve as either an alternative pathogenetic mechanism or secondary mutations. Here, we review recent advances in our understanding of the molecular pathogenesis of ameloblastoma as well as the diagnostic, prognostic, and therapeutic implications of these discoveries.
Insights
Ameloblastoma pathogenesis involves key mutations in FGFR2, BRAF, and RAS, activating MAPK signaling. The role of sonic hedgehog (SHH) pathway mutations remains under investigation for this odontogenic neoplasm.
Area of Science:
- Oral pathology
- Molecular oncology
- Cancer genetics
Background:
- Ameloblastoma is a common odontogenic neoplasm with incompletely understood molecular drivers.
- Recent research has identified significant genetic alterations in ameloblastoma development.
Purpose of the Study:
- To review recent advances in understanding ameloblastoma's molecular pathogenesis.
- To discuss the diagnostic, prognostic, and therapeutic implications of these molecular discoveries.
Main Methods:
- Literature review of recent studies on ameloblastoma molecular pathogenesis.
- Analysis of genetic mutations in key signaling pathways.
Main Results:
- Recurrent activating mutations in FGFR2, BRAF, and RAS are prevalent in ameloblastomas.
- These mutations implicate MAPK pathway dysregulation in tumor pathogenesis.
- The role of sonic hedgehog (SHH) pathway mutations (e.g., SMO) is debated, potentially representing alternative or secondary events.
Conclusions:
- Understanding ameloblastoma's molecular landscape, particularly MAPK pathway activation, is crucial.
- Further research is needed to clarify the role of SHH pathway alterations.
- Molecular insights offer potential for improved diagnosis, prognosis, and targeted therapies for ameloblastoma.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...